This includes not only serum and immune biomarkers but also tumor-intrinsic biomarkers of immune competence, such as the expression of proteins that regulate key pathways, like cGAS-STING (e.g., RECQL4, TRIM6), which may stratify patients who are likely to need additional innate immune agonists [152,153]. This evidence concerns the gene TRIM6 and neoplasm.